Adicet Bio, Inc. (ACET)

Insider Trading Filed: 2026-04-29

Key Insights

• RA Capital Healthcare Fund exchanged 250,000 shares of common stock for pre-funded warrants at an exercise price of $0.0001 per share, suggesting confidence in the company's future value while maintaining a 9.99% ownership cap.
• The pre-funded warrant has no expiration date and is exercisable immediately, giving RA Capital significant flexibility to increase ownership position while preserving liquidity and downside protection through the nominal exercise price.
• RA Capital Management and affiliated entities (including partners Peter Kolchinsky and Rajeev Shah) maintain director and 10% owner status, indicating sustained institutional backing from a sophisticated healthcare-focused investment firm.
• The exchange transaction structure demonstrates a strategic repositioning from common stock to warrant equivalents, which typically signals management expects stock appreciation while managing dilution concerns for existing shareholders.

Sentiment: Positive Significance: 6/10

View Original Filing →

Current Report Filed: 2026-04-28

Key Insights

• RA Capital exchanged 250,000 existing common shares for a pre-funded warrant, representing a strategic refinancing that allows the investor to maintain upside exposure while reducing immediate equity dilution.
• The pre-funded warrant's $0.0001 exercise price is nominal, making it virtually certain to be exercised, effectively converting this into a delayed equity issuance rather than a traditional financing.
• The 9.99% beneficial ownership blocker with ability to increase to 19.99% upon notice suggests RA Capital negotiated significant shareholder protections while preserving optionality to increase its stake.
• The Section 3(a)(9) exemption used for this transaction indicates it was structured as a private exchange rather than a public offering, minimizing regulatory burden but limiting capital raised.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-04-13

Key Insights

• RA Capital Management, L.P. has been steadily increasing its stake in Adicet Bio, Inc. (ACET), purchasing over 223,000 shares in the past three trading days.
• The purchases were made at prices ranging from $7.04 to $7.27 per share, indicating that RA Capital believes the stock is currently undervalued.
• RA Capital, along with its affiliated entities, now holds a significant 10% ownership stake in Adicet Bio, suggesting they have a strong interest in the company's long-term performance.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-04-09

Key Insights

• OrbiMed Advisors LLC and its affiliates have reported significant ownership (over 10%) in Adicet Bio, Inc. (ACET), indicating their strong interest in the company.
• The SEC Form 4 filing shows that OrbiMed entities have been actively trading ACET shares, with both purchases and sales reported in the period covered.
• The trading patterns suggest that OrbiMed may be strategically managing its position in ACET, potentially taking advantage of market movements to optimize its investment.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-03-27

Key Insights

• Blake Aftab, the Chief Scientific Officer of Adicet Bio, Inc. (ACET), acquired 72,555 stock options with an exercise price of $6.81 on March 25, 2026, indicating his confidence in the company's future prospects.
• The stock options will vest over a 4-year period, aligning Aftab's interests with those of long-term shareholders and suggesting his commitment to the company's long-term success.
• Insider buying, especially by a key executive like the Chief Scientific Officer, is often viewed positively by investors as a sign of management's belief in the company's growth potential.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-03-27

Key Insights

• Don Healey, the Chief Technology Officer of Adicet Bio, Inc. (ACET), has acquired 43,361 stock options on March 25, 2026, with an exercise price of $6.81 and a vesting schedule of 1/48th per month over the next 4 years.
• Insider buying by the Chief Technology Officer could signal the company's confidence in its future prospects and may be seen positively by investors.
• The large number of options granted to the executive suggests Adicet Bio is focused on retaining and incentivizing its key technical talent to drive the company's growth and development.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-03-27

Key Insights

• Julia D. Maltzman, the Chief Medical Officer of Adicet Bio, Inc. (ACET), acquired 72,555 stock options with an exercise price of $6.81 on March 25, 2026, vesting over 48 months.
• The acquisition of these stock options suggests Maltzman's confidence in the company's future and aligns her incentives with those of shareholders.
• Insider transactions, such as this option grant, can provide insights into management's perspective on the company's prospects and may be viewed positively by investors.

Sentiment: Positive Significance: 5/10

View Original Filing →

Insider Trading Filed: 2026-03-27

Key Insights

• Insider Chen Schor, the President and CEO of Adicet Bio, acquired a new stock option grant of 468,555 shares with a strike price of $6.81 on March 25, 2026. This could indicate their confidence in the company's future prospects.
• The stock option grant vests over a 4-year period, with 1/48th of the shares vesting monthly, suggesting a long-term commitment from the CEO.
• The timing of this insider purchase, coming shortly before the filing date, may be viewed positively by investors as a sign of management's belief in the company's growth potential.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-03-27

Key Insights

• Brian Nicholas Harvey, the Chief Financial Officer of Adicet Bio, Inc., has acquired 43,361 stock options with an exercise price of $6.81 and a vesting period of 48 months.
• The acquisition of these stock options indicates that the CFO is bullish on the company's long-term prospects and aligns his interests with those of shareholders.
• The timing of the transaction, occurring on March 25, 2026, suggests the CFO has confidence in the company's future performance and believes the stock is undervalued at the current price.

Sentiment: Positive Significance: 7/10

View Original Filing →

Insider Trading Filed: 2026-01-27

Key Insights

• The reporting person, Brian Nicholas Harvey, is the Chief Financial Officer of Adicet Bio, Inc.
• Harvey disposed of 546 shares of Adicet Bio's common stock on January 24, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Harvey now owns 5,145 shares of Adicet Bio's common stock directly, a decrease from his previous holding.

Sentiment: Neutral Significance: 3/10

View Original Filing →

Insider Trading Filed: 2026-01-27

Key Insights

• The reporting person, Chen Schor, is the President and CEO of Adicet Bio, Inc. (ACET), as well as a director of the company.
• Schor disposed of 1,755 shares of ACET common stock on January 24, 2026, likely to satisfy tax withholding obligations related to the vesting of restricted stock units.
• Schor beneficially owns a total of 12,875 shares of ACET common stock, with 6,820 shares held directly and 6,055 shares held indirectly through two family trusts.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Insider Trading Filed: 2026-01-27

Key Insights

• The reporting person, Don Healey, is the Chief Technology Officer of Adicet Bio, Inc. and has disposed of 535 shares of common stock through a stock withholding transaction to satisfy tax obligations.
• The share disposal represents a small portion (around 13%) of the reporting person's total beneficial ownership of 3,452 shares of common stock in the company.
• The transaction appears to be a routine stock withholding event, likely done to cover tax liabilities associated with the vesting of restricted stock units, rather than a voluntary sale.

Sentiment: Neutral Significance: 3/10

View Original Filing →

Insider Trading Filed: 2026-01-27

Key Insights

• The reporting person, Blake Aftab, appears to be the Chief Scientific Officer of Adicet Bio, Inc. (ACET) and owns 2,981 shares of the company's common stock after the reported transaction.
• The transaction on January 24, 2026, involves the withholding of 535 shares by the issuer to satisfy tax obligations related to the vesting of restricted stock units, which does not represent a sale by the reporting person.
• The filing reflects a 1-for-16 reverse stock split effected by the issuer on December 30, 2025, which should be taken into account when analyzing the reported share ownership.

Sentiment: Neutral Significance: 4/10

View Original Filing →

Current Report Filed: 2026-01-07

Key Insights

• Adicet Bio has doubled enrollment in its prulacabtagene leucel (prula-cel) Phase 1 program for autoimmune diseases, indicating progress in its clinical development.
• The company has reached alignment with the FDA to allow patients with lupus nephritis and systemic lupus erythematosus to be dosed with prula-cel in the outpatient setting, potentially improving access and convenience for patients.
• Adicet plans to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in the first half of 2026, potentially expanding its pipeline and addressing an unmet medical need.

Sentiment: Positive Significance: 7/10

View Original Filing →